Research programme: oxazolidinone antibacterials - JMI Laboratories

Drug Profile

Research programme: oxazolidinone antibacterials - JMI Laboratories

Alternative Names: LCB-229; LCB-647; LCB-648; LCB-676

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator JMI Laboratories
  • Class Oxazolidinones
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Gram-positive infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Gram-positive-infections in USA
  • 20 Sep 2011 Early research in Gram-positive infections in USA (unspecified route)
  • 20 Sep 2011 Antimicrobial data from Early research trial in Gram-positive infections presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top